The clear rejection by the Board of AstraZeneca to Pfizer may not necessarily mean a permanent end to a deal. This reports reveals what the Board needs to hear and the possibility of such taking place.
This report available to consulting clients of CT Capital LLC. Contact kenhackel@ctcapllc.com or gailtrokie@ctcapllc.com for information
